We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App





Ortho Presents Broad Menu of High-Performing Assays at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 11 Apr 2022

Ortho Clinical Diagnostics (Raritan, NJ, USA) presented its comprehensive, fully integrated and completely scalable solutions, including its broad menu of high-performing assays, at EUROMEDLAB 2022. More...

Ortho presented its VITROS Dashboards, a web-based system designed to provide productivity information regarding analyzers, test volumes, workload balance, HIT (Hemolysis, Icterus, Turbidity) levels, and reagent efficiency. The highlight of Ortho’s presentation at EUROMEDLAB 2022 was its VITROS COVID-19 Performance Dashboard - a web-based system designed to provide productivity information regarding Ortho analyzers, including volumes, workload balance, HIT levels, and reagent efficiency for each site within the health system. The VITROS COVID-19 Performance Dashboard is located within the Ortho Plus environment and is an extension of Ortho’s e-Connectivity Technology. e-Connectivity not only supports the delivery of timely and accurate results to patients and physicians, it also protects patient data.

With the ability to monitor antibody testing trends, users can adjust staffing and workflow according to their testing volumes. Labs can quantify the number of samples processed the first time - even when HIT interference is present, giving them the ability to spot negative trends in order to take action. With the VITROS COVID-19 Performance Dashboard, users have access to data that will give them a better understanding of the virus, including its impact on their lab and hospital, to adjust accordingly. With signal to cut off values, labs can see the separation between positive and negative results, giving them confidence in their results. The VITROS COVID-19 Performance Dashboard assisting users in their quest to improve laboratory efficiency and decision support while providing the best care for their patients and staff.

IN Addition, Ortho demonstrated how laboratories can contribute to patient blood management initiatives by minimizing impact of common interferences amongst other challenges. The company also exhibited its broad menu of high-performing assays that are optimized to meet the changing testing needs of laboratories.

Related Links:
Ortho Clinical Diagnostics 


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Ultra-Low Temperature Freezer
iUF118-GX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.